



Form PTO-1449
 U.S. DEPARTMENT OF COMMERCE
 PATENT AND TRADEMARK OFFICE

LIST OF INFORMATION CITED BY APPLICANT
 (Use as many sheets as necessary)

Complete if Known	
Application Number	10/650,260
Filing Date	August 27, 2003
First Named Inventor	Poynard
Group Art Unit	Unassigned
Examiner Name	Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	*A1	5,935,798	08/10/1999	Prie et al.	435	7.23	
	*A2	4,312,853	01/26/1982	Timpl	424	1	

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document Country Code Number Kind Code	Date	Name	Translation Yes/No
	*A3	EP 0 911 343 A2	04/28/1999	Tesoh Corporation	
	*A4	WO 01/86304 A2	11/15/2001	Bayer Aktiengesellschaft	

NON-PATENT DOCUMENTS

Examiner's Initials	Cite No.	Non-Patent Citations (Include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
	*A5	Bedossa et al., "Apolipoprotein AI is a Serum and Tissue Marker of Liver Fibrosis in Alcoholic Patients." <i>Alcohol Clin. Exp. Res.</i> 13(6):829-833 (November/December 1989)
	*A6	Gabrielli et al., "Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis." <i>Clin. Chim. Acta</i> 265:21-31 (1997)
	*A7	Guechot et al., "Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis." <i>Clin Chem.</i> 42(4):558-563 (1996)
	*A8	Johnston, "Special Considerations in Interpreting Liver Function Tests." <i>Am. Fam. Physician</i> pp. 1-11 (April 15, 1999) www.aafp.org/afp/990415ap/2223.html (Print Date of February 8, 2002)
	*A9	Kasahara et al., "Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response." <i>J. Hepatol.</i> 26(3):574-583 (March 1997)
	*A10	Kropf et al., "Efficacy of Serum Laminin Measurement for Diagnosis of Fibrotic Liver Diseases." <i>Clin. Chem.</i> 34(10):2026-2030 (1988)
	*A11	Naveau et al., "Alpha-2-Macroglobulin and Hepatic Fibrosis. Diagnostic Interest." <i>Dig. Dis. Sci.</i> 39(11):2426-2432 (November 1994)
	*A12	Oberti et al., "Noninvasive Diagnosis of Hepatic Fibrosis or Cirrhosis." <i>Gastroenterology</i> 113(5):1609-1616 (November 1997)
	*A13	Pilette et al., "Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers." <i>J. Hepatol.</i> 28(3):439-446 (March 1998)
<i>JB</i>	*A14	Poynard and Bedossa, "Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus." METAVIR and CLINIVIR Cooperative Study Groups. <i>J. Viral Hepat.</i> 4(3):199-208 (May 1997)



**ATTORNEY DOCKET NO. 03225.0001U2
APPLICATION NO. 10/650,260
SHEET 2 OF 2**

	*A15	Poynard et al., "Natural history of liver fibrosis progression in patients with chronic hepatitis C." The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC Groups. <i>Lancet</i> 349(9055):825-832 (March 22, 1997)
	*A16	Teare et al., "Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis." <i>Lancet</i> 342:895-898 (October 9, 1993)
	*A17	Wong et al., "Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection." <i>J. Viral Hepat.</i> 5:187-192 (May 1998)